Katzman P L, Hulthén U L, Hökfelt B
Department of Endocrinology, University of Lund, Malmö General Hospital, Sweden.
Horm Metab Res. 1987 Sep;19(9):426-9. doi: 10.1055/s-2007-1011843.
Studies were performed to explore the effect of calcium antagonism with felodipine for 8 weeks on glucose homeostasis and serum lipids in 8 patients with essential hypertension. Fasting levels of blood glucose as well as serum C-peptide, insulin, glucagon and free fatty acids were unchanged following felodipine. During an intravenous glucose tolerance test, the incremental area under the curve for C-peptide and glucose was unchanged, but decreased for insulin, after felodipine. The decremental area over the curve for glucagon and free fatty acids remained unchanged. Fasting serum total cholesterol and high density lipoprotein cholesterol were unaltered, whereas triglycerides decreased following felodipine. The findings indicate that calcium antagonism with felodipine does not affect glucose-induced insulin release in vivo. The increased insulin clearance could be expected to be coupled to a change in glucose tolerance, but this was unaltered during long-term calcium antagonism.
开展了多项研究,以探究使用非洛地平进行8周钙拮抗治疗对8例原发性高血压患者糖稳态和血脂的影响。非洛地平治疗后,空腹血糖水平以及血清C肽、胰岛素、胰高血糖素和游离脂肪酸水平均未发生变化。在静脉葡萄糖耐量试验期间,非洛地平治疗后,C肽和葡萄糖的曲线下增量面积未变,但胰岛素的曲线下增量面积减小。胰高血糖素和游离脂肪酸的曲线下减量面积保持不变。空腹血清总胆固醇和高密度脂蛋白胆固醇未改变,而非洛地平治疗后甘油三酯降低。这些研究结果表明,使用非洛地平进行钙拮抗治疗不会影响体内葡萄糖诱导的胰岛素释放。胰岛素清除率增加可能会导致葡萄糖耐量改变,但在长期钙拮抗治疗期间,葡萄糖耐量并未改变。